Rinat Yerushalmi

9.4k total citations · 5 hit papers
119 papers, 6.7k citations indexed

About

Rinat Yerushalmi is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rinat Yerushalmi has authored 119 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Oncology, 52 papers in Cancer Research and 35 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rinat Yerushalmi's work include Breast Cancer Treatment Studies (43 papers), BRCA gene mutations in cancer (27 papers) and Advanced Breast Cancer Therapies (19 papers). Rinat Yerushalmi is often cited by papers focused on Breast Cancer Treatment Studies (43 papers), BRCA gene mutations in cancer (27 papers) and Advanced Breast Cancer Therapies (19 papers). Rinat Yerushalmi collaborates with scholars based in Israel, United States and Canada. Rinat Yerushalmi's co-authors include Karen A. Gelmon, Ryan Woods, Hagen F. Kennecke, Caroline Speers, Maggie C.U. Cheang, Malcolm Hayes, David Voduc, Torsten O. Nielsen, Peter M. Ravdin and Anthony Gonçalvès and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Rinat Yerushalmi

112 papers receiving 6.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Metastatic Behavior of Breast Cancer Subtypes

2010 1.6k citations Rinat Yerushalmi et al. profile →
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

2018 1.4k citations Jennifer K. Litton, Hope S. Rugo et al. New England Journal of Medicine profile →
Ki67 in breast cancer: prognostic and predictive potential

2010 899 citations Rinat Yerushalmi et al. profile →
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

2011 850 citations Rinat Yerushalmi et al. profile →
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

2020 252 citations Jennifer K. Litton, Sara A. Hurvitz et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Rinat Yerushalmi

Since Specialization

Citations

This map shows the geographic impact of Rinat Yerushalmi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rinat Yerushalmi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rinat Yerushalmi more than expected).

Fields of papers citing papers by Rinat Yerushalmi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rinat Yerushalmi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rinat Yerushalmi. The network helps show where Rinat Yerushalmi may publish in the future.

Co-authorship network of co-authors of Rinat Yerushalmi

This figure shows the co-authorship network connecting the top 25 collaborators of Rinat Yerushalmi. A scholar is included among the top collaborators of Rinat Yerushalmi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rinat Yerushalmi. Rinat Yerushalmi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Chemotherapy-Induced Cell-Surface GRP78 Expression as a Prognostic Marker for Invasiveness of Metastatic Triple-Negative Breast Cancer 2025 ·Annals of Biomedical Engineering ·Martha B. Alvarez‐Elizondo, Annat Raiter, Rinat Yerushalmi, Daphne Weihs	1
2	Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry 2023 ·npj Breast Cancer ·Shlomit Strulov Shachar, Michelle Leviov, Rinat Yerushalmi, Karen Drumea, (unknown), Lior Soussan‐Gutman, Avital Bareket‐Samish, Amir Sonnenblick, (unknown), Ella Evron, Einav Nili Gal‐Yam, Shani Paluch–Shimon, Gil Bar‐Sela, Hadar Goldvaser, Salomon M. Stemmer	1
3	192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC) 2023 ·ESMO Open ·David Cameron, William Jacot, Toshinari Yamashita, María Vidal, Peter Schmid, (unknown), Michelino De Laurentiis, Flora Zagouri, Naoto T. Ueno, Aleix Prat, Nadia Harbeck, Rinat Yerushalmi, Yen‐Shen Lu, Andrea Gombos, (unknown), (unknown), Lotus Yung, (unknown), Junji Tsurutani, Shanu Modi	3
4	149P Clinical outcomes in ER+ breast cancer patients with recurrence score 26-30-guided therapy: Real-world data 2022 ·Annals of Oncology ·(unknown), (unknown), Michelle Leviov, Iryna Kuchuk, (unknown), (unknown), Shani Paluch–Shimon, Ofra Maimon, Rinat Yerushalmi, (unknown), Ella Evron, Amir Sonnenblick, Einav Nili Gal‐Yam, Hadar Goldvaser, (unknown), (unknown), (unknown), (unknown), Salomon M. Stemmer	1
5	Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis 2022 ·Breast Cancer Research and Treatment ·(unknown), Daliah Tsoref, Ahuva Grubstein, (unknown), (unknown), (unknown), Hadar Goldvaser, Ilan Feldhamer, (unknown), Tzippy Shochat, Eran Sharon, Inbal Kedar, Rinat Yerushalmi	1
6	The impact of endogenous estrogen exposures on the characteristics and outcomes of estrogen receptor positive, early breast cancer 2021 ·Discover Oncology ·(unknown), (unknown), (unknown), Assaf Moore, Tzippy Shochat, Rinat Yerushalmi, Hadar Goldvaser	2
7	Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial breakdown → 2020 ·Annals of Oncology ·Jennifer K. Litton, Sara A. Hurvitz, Lida A. Mina, Hope S. Rugo, Ki Hoon Lee, Anthony Gonçalvès, Sami Diab, Natasha Woodward, Annabel Goodwin, Rinat Yerushalmi, Henri Roché, Young‐Hyuck Im, W. Eiermann, Ruben G.W. Quek, Tiziana Usari, Silvana Lanzalone, Akos Czibere, Joanne L. Blum, Miguel Martín, Johannes Ettl	252
8	National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study 2020 ·Cancer Treatment Reviews ·(unknown), Eitan Amir, Ariadna Tibau, Rinat Yerushalmi, Assaf Moore, Daniel Shepshelovich, Hadar Goldvaser	5
9	GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment 2020 ·BMC Cancer ·Annat Raiter, (unknown), Ido Lubin, Rinat Yerushalmi	9
10	Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation breakdown → 2018 ·New England Journal of Medicine ·Jennifer K. Litton, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalvès, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A. Mina, Miguel Martín, Henri Roché, Young‐Hyuck Im, Ruben G.W. Quek, Denka Markova, Iulia Cristina Tudor, Alison L. Hannah, W. Eiermann, Joanne L. Blum	1401
11	Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation 2018 ·Cancer Research ·Jennifer K. Litton, HS Rugo, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalvès, Kyung Ho Lee, Louis Fehrenbacher, Rinat Yerushalmi, (unknown), Miguel Martín, Henri Roché, Y-H Im, (unknown), (unknown), (unknown), W. Eiermann, JL Blum	40
12	The association between smoking and breast cancer characteristics and outcome 2017 ·BMC Cancer ·Hadar Goldvaser, (unknown), Shulamith Rizel, Daniel Hendler, Victoria Neiman, Tzippy Shochat, Aarón Sulkes, Baruch Brenner, Rinat Yerushalmi	24
13	The Association between Angiotensin Receptor Blocker Usage and Breast Cancer Characteristics 2016 ·Oncology ·Hadar Goldvaser, Shulamit Rizel, Daniel Hendler, Victoria Neiman, Daniel Shepshelovich, Tzippy Shochat, Aarón Sulkes, Baruch Brenner, Rinat Yerushalmi	4
14	Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations 2016 ·Breast Cancer Research and Treatment ·(unknown), Aarón Sulkes, Tzippy Shochat, Daliah Tsoref, Shulamith Rizel, Nicky Liebermann, Daniel Hendler, Victoria Neiman, Irit Ben‐Aharon, Eitan Friedman, Shani Paluch–Shimon, David Margel, Inbal Kedar, Rinat Yerushalmi	29
15	The 21-Gene Recurrence Score Assay (Oncotype DX™) in Estrogen Receptor-Positive Male Breast Cancer: Experience in an Israeli Cohort 2014 ·Oncology ·Tal Grenader, Rinat Yerushalmi, (unknown), Georgeta Fried, Bella Kaufman, Tamar Peretz, David Geffen	26
16	Adjuvant Docetaxel and Cyclophosphamide (DC) with Prophylactic Granulocyte Colony-Stimulating Factor (G-CSF) on Days 8 &12 in Breast Cancer Patients: A Retrospective Analysis 2014 ·PLoS ONE ·Rinat Yerushalmi, Hadar Goldvaser, Aarón Sulkes, Irit Ben‐Aharon, Daniel Hendler, Victoria Neiman, (unknown), Luisa Bonilla, (unknown), Alona Zer, (unknown), Shulamith Rizel, Salomon M. Stemmer	7
17	Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis 2013 ·Journal of Neuro-Oncology ·Shlomit Yust‐Katz, (unknown), D. Liu, Yuan Yuan, (unknown), Rinat Yerushalmi, Marta Penas‐Prado, Morris D. Groves	42
18	Phase II Study of Concurrent Capecitabine and External Beam Radiotherapy for Pain Control of Bone Metastases of Breast Cancer Origin 2013 ·PLoS ONE ·Yulia Kundel, Nicola J. Nasser, Ofer Purim, Rinat Yerushalmi, Eyal Fenig, Raphael M. Pfeffer, Salomon M. Stemmer, Shulamith Rizel, Zvi Symon, Bella Kaufman, Aarón Sulkes, Baruch Brenner	6
19	Tailoring Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Historical Prospective Study 2012 ·Chemotherapy ·Alona Zer, Shulamit Rizel, Rony Braunstein, Rinat Yerushalmi, Daniel Hendler, (unknown), (unknown), Aarón Sulkes, Salomon M. Stemmer	1
20	Treatment of Neuroblastoma Using the Fused Imaging Guided Radiotherapy (FIGURA) System 2006 ·Clinical Nuclear Medicine ·Eyal Fenig, Moshe Mishaeli, Rinat Yerushalmi, (unknown), (unknown), Liora Kornreich, (unknown), Adam Steinmetz	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact